Childhood cancers trials in China

In China 608 Also abroad 2481

608 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Not yet taking people in China
CAR-T Immunotherapy Targeting CD19- ALL
Where
Shenzhen
Age
6 months to 75 years
People
100
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT04016129
Phase 1/2Not yet taking people in China
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
Where
Shenzhen
Age
6 months to 75 years
People
30
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT04033302
Phase 1/2Not yet taking people in China
Multi-CAR-T Cells Targeting B Cell Lymphomas
Where
Shenzhen
Age
6 months to 75 years
People
11
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT04429438
Phase 1/2Not yet taking people in China
Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276
Where
Shenzhen
Age
1 year to 75 years
People
100
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT04432649
Phase 1/2Not yet taking people in China
Combination Immunotherapy Targeting Sarcomas
Where
Shenzhen
Age
1 year to 75 years
People
20
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT04433221
Phase 1/2Not yet taking people in China
CD19/22 Bi-specific CAR-T Cell Therapy
Where
Shenzhen
Age
6 months to 75 years
People
60
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT05432882
Phase 1/2Not yet taking people in China
CD19/70 Bi-specific CAR-T Cell Therapy
Where
Shenzhen
Age
6 months to 75 years
People
30
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT05436496
Phase 1/2Not yet taking people in China
GD2/PSMA Bi-specific CAR-T Cell Therapy
Where
Shenzhen
Age
1 year to 75 years
People
60
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT05437315
Phase 1/2Not yet taking people in China
GD2/CD70 Bi-specific CAR-T Cell Therapy
Where
Shenzhen
Age
1 year to 75 years
People
30
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT05438368
Phase 1Not yet taking people in China
Universal 4SCAR7U Targeting CD7-positive Malignancies
Where
Shenzhen
Age
6 months to 75 years
People
30
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT05995028
Phase 1Not yet taking people in China
Universal CAR-T Cells Targeting AML
Where
Shenzhen
Age
6 months to 75 years
People
30
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT05995041
Phase 1/2Not yet taking people in China
DLL3 CAR-T Therapy Targeting Brain Tumors
Where
Shenzhen
Age
2 years to 70 years
People
30
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT07180927
Phase 1/2Not yet taking people in China
Study on GD2 Positive Solid Tumors by 4SCAR-GD2
Where
Shenzhen
Age
1 year to 65 years
People
10
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT02992210
Phase 1/2Not yet taking people in China
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
Where
Shenzhen
Age
1 year to 75 years
People
20
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT03356782
Phase 1Not yet taking people in China
Immune Modulatory DC Vaccine Against Brain Tumor
Where
Shenzhen
Age
1 year to 75 years
People
10
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT03914768
Phase 1/2Not yet taking people in China
PSMA-specific CAR-T Cell Therapy
Where
Shenzhen
Age
1 year to 75 years
People
100
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT04429451
Phase 1/2Not yet taking people in China
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
Where
Shenzhen
Age
1 year to 65 years
People
100
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT04637503
Phase 1/2Taking people
A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
Where
Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Shijiazhuang, Tianjin, Wuhan, Xuzhou, Zhengzhou
Age
2 years and over
People
203
Run by
MSD R&D (China) Co., Ltd.
See details and how to joinNCT05579132
Phase 1Not yet taking people in China
4SCAR19U T Cells Targeting B Cell Malignancies
Where
Shenzhen
Age
6 months to 75 years
People
30
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT05995015
Phase 1/2Not yet taking people in China
H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
Where
Shenzhen
Age
2 years to 70 years
People
30
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT07501156
Phase 4Taking people
Safety and Efficacy of Belzutifan in Preoperative Preparation for Patients With Pheochromocytoma/Paraganglioma (PPGL)
Where
Changsha
Age
14 years to 85 years
People
20
Run by
Longfei Liu，MD
See details and how to joinNCT07907341
No phaseTaking people
Hydrogel Spacer During Definitive Radiotherapy for Cervical Cancer
Where
Tianjin
Age
17 years to 75 years
People
30
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07904182
No phaseTaking people
A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients
Where
Beijing, Changsha, Chengdu, Guangzhou, Haerbin, Jinan, Nantong, Shanghai, Shenyang, Suzhou, Ürümqi, Zhejiang
People
2,100
Run by
AstraZeneca
See details and how to joinNCT07404202
Phase 2Not yet taking people in China
Selumetinib for NF2-Related Schwannomatosis
Where
Beijing
Age
3 years and over
People
20
Run by
Beijing Tiantan Hospital
See details and how to joinNCT07707947
Early phase 1Taking people
mRNA Vaccine for Advanced Lung Cancer and Pulmonary Metastases of Solid Tumors
Where
Beijing
Age
Up to 99 years
People
83
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06928922